R. Gambhira

发表

Dendritic cells enhance detection of antigen‐specific cellular immune responses by lymphocytes from rhesus macaques immunized with an HIV envelope peptide cocktail vaccine

P. Nehete, K. Sastry, B. Nehete, 2003, Journal of medical primatology.

HPV16 L1 capsid protein expressed from viable adenovirus recombinants elicits neutralizing antibody in mice.

E. Hoiczyk, R. Roden, G. Ketner, 2007, Vaccine.

Interaction of tSNARE Syntaxin 18 with the Papillomavirus Minor Capsid Protein Mediates Infection

I. Bossis, P. Howley, R. Roden, 2005, Journal of Virology.

Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species.

P. Stern, I. Bossis, R. Roden, 2006, Cancer research.

Transmitted/Founder Simian Immunodeficiency Virus Envelope Sequences in Vesicular Stomatitis and Semliki Forest Virus Vector Immunized Rhesus Macaques

D. Montefiori, B. Keele, P. Marx, 2014, PloS one.

Serological relationship between cutaneous human papillomavirus types 5, 8 and 92.

M. Favre, O. Forslund, S. Shafti-Keramat, 2009, The Journal of general virology.

Expression pattern and subcellular localization of human papillomavirus minor capsid protein L2.

R. Roden, C. Meyers, P. Gravitt, 2009, The American journal of pathology.

Immunopathology and Infectious Diseases Expression Pattern and Subcellular Localization of Human Papillomavirus Minor Capsid Protein L 2

R. Roden, C. Meyers, P. Gravitt, 2008 .

Concatenated Multitype L2 Fusion Proteins as Candidate Prophylactic Pan-Human Papillomavirus Vaccines

D. Lowy, R. Roden, J. Schiller, 2009, Journal of the National Cancer Institute.

Protection of Rabbits against Challenge with Rabbit Papillomaviruses by Immunization with the N Terminus of Human Papillomavirus Type 16 Minor Capsid Antigen L2

R. Roden, N. Christensen, B. Karanam, 2007, Journal of Virology.

Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2.

D. Lowy, R. Roden, J. Schiller, 2005, Virology.

Concatenated Multitype L2 Fusion Proteins as Candidate Prophylactic Pan-Human Papillomavirus Vaccines

D. Lowy, R. Roden, J. Schiller, 2009, Journal of the National Cancer Institute.

Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2

R. Roden, J. Schiller, D. Jackson, 2008, Proceedings of the National Academy of Sciences.

Serological relationship between cutaneous human papillomavirus types 5, 8 and 92

M. Favre, O. Forslund, S. Shafti-Keramat, 2008 .

A Protective and Broadly Cross-Neutralizing Epitope of Human Papillomavirus L2

I. Bossis, R. Roden, N. Christensen, 2007, Journal of Virology.

Mechanisms of Human Papillomavirus Type 16 Neutralization by L2 Cross-Neutralizing and L1 Type-Specific Antibodies

D. Lowy, R. Roden, J. Schiller, 2008, Journal of Virology.

A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11.

R. Roden, N. Christensen, S. Shafti-Keramat, 2007, Vaccine.

Role of L2 cysteines in papillomavirus infection and neutralization

R. Roden, B. Karanam, P. Day, 2009, Virology Journal.

Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity.

P. Stern, R. Roden, B. Karanam, 2009, Vaccine.

Immune Responses in Macaques to a Prototype Recombinant Adenovirus Live Oral Human Papillomavirus 16 Vaccine

A. Scott, R. Roden, G. Ketner, 2014, Clinical and Vaccine Immunology.

Generation and characterization of a preventive and therapeutic HPV DNA vaccine.

T. Wu, B. Karanam, C. Hung, 2008, Vaccine.

A two-codon mutant of cholera toxin lacking ADP-ribosylating activity functions as an effective adjuvant for eliciting mucosal and systemic cellular immune responses to peptide antigens.

J. Peterson, A. Chopra, D. Lomada, 2004, Vaccine.

Intranasal immunization with synthetic peptides corresponding to the E6 and E7 oncoproteins of human papillomavirus type 16 induces systemic and mucosal cellular immune responses and tumor protection.

A. Chopra, Amy N. Courtney, P. Nehete, 2007, Vaccine.

Significant Protection against High-Dose Simian Immunodeficiency Virus Challenge Conferred by a New Prime-Boost Vaccine Regimen

D. Montefiori, P. Marx, J. Rose, 2011, Journal of Virology.

Antigenic requirement for Gag in a vaccine that protects against high-dose mucosal challenge with simian immunodeficiency virus.

P. Marx, J. Rose, L. Buonocore, 2015, Virology.

Antigenic requirement for Gag in a vaccine that protects against high-dose mucosal challenge with simian immunodeficiency virus.

P. Marx, J. Rose, L. Buonocore, 2015, Virology.